← Leaderboards
Warner King Huh
University Of Alabama At Birmingham
$4,442,806
Attributed
$6,912,921
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,123,882 · 6
By mechanism
P50$8,658,819 · 4
R01$2,465,063 · 2
Top collaborators
- Richard Bruce Roden11 shared
- Robert L Garcea6 shared
- Simon Manga3 shared
- Pius Muffih Tih2 shared
- T.-C. Wu2 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Simon Manga$464,381
- Pius Muffih Tih$183,599
Others in their field
Top investigators on “Malignant Neoplasm Of Cervix Uteri”
- David Heimbrook · Leidos Biomedical Research, Inc.$177,328,706
- Philip J Disaia · University Of California Irvine$75,863,106
- Walter John Curran · Thomas Jefferson University$47,862,860
- Larry Arthur$27,902,757
- Norman Wolmark · Nsabp Foundation, Inc.$21,221,311
- T.-C. Wu · Howard University$18,468,441
Research focus
Malignant Neoplasm Of Cervix UteriHuman PapillomavirusDoseVaginaWomanVaccinesHuman Papilloma Virus VaccineAntigensHuman Papillomavirus 16Virus-Like ParticleVaccinationCostWomen&AposProgramsMalignant NeoplasmsVaccinatedAntibodiesNeutralizing AntibodyInfectionBaseAdjuvantOncogenicDeveloping CountriesVaccine Development
Grant awards (24)
SPORE in Cervical Cancer$2,261,467
P50 · FY2025 · CA
Misoprostol to Optimize Prevention of Cancer of the Cervix: A Randomized Trial (MISOPCx Project)$435,430
R01 · FY2025 · CA · contact PI
Misoprostol to Optimize Prevention of Cancer of the Cervix: A Randomized Trial (MISOPCx Project)$115,366
R01 · FY2025 · CA · contact PI
SPORE in Cervical Cancer$1,949,494
P50 · FY2024 · CA
Misoprostol to Optimize Prevention of Cancer of the Cervix: A Randomized Trial (MISOPCx Project)$561,565
R01 · FY2024 · CA · contact PI
Thermostable RG1-VLPs, a candidate broadly protective HPV vaccine for the prevention of cervical cancer$377,621
P50 · FY2023 · CA · contact PI
Thermostable RG1-VLPs, a candidate broadly protective HPV vaccine for the prevention of cervical cancer$429,218
P50 · FY2022 · CA · contact PI
Thermostable RG1-VLPs, a candidate broadly protective HPV vaccine for the prevention of cervical cancer$208,552
P50 · FY2021 · CA · contact PI
Thermostable RG1-VLPs, a candidate broadly protective HPV vaccine for the prevention of cervical cancer$349,933
P50 · FY2020 · CA · contact PI
L1 capsomeres as a next generation preventive HPV vaccine$303,911
P50 · FY2013 · CA
Development of a Pan-Oncogenic HPV Preventive Vaccine$247,234
P50 · FY2013 · CA
L1 capsomeres as a next generation preventive HPV vaccine$111,720
P50 · FY2013 · CA
L1 capsomeres as a next generation preventive HPV vaccine$325,893
P50 · FY2012 · CA
Development of a Pan-Oncogenic HPV Preventive Vaccine$264,933
P50 · FY2012 · CA
A Phase I Study to Evaluate the Safety and Immunogenicity of HPV 16 L2 11-200$255,953
R01 · FY2012 · CA · contact PI
L1 capsomeres as a next generation preventive HPV vaccine$319,954
P50 · FY2011 · CA
Development of a Pan-Oncogenic HPV Preventive Vaccine$262,026
P50 · FY2011 · CA
A Phase I Study to Evaluate the Safety and Immunogenicity of HPV 16 L2 11-200$329,787
R01 · FY2010 · CA · contact PI
L1 capsomeres as a next generation preventive HPV vaccine$310,410
P50 · FY2010 · CA
Development of a Pan-Oncogenic HPV Preventive Vaccine$310,397
P50 · FY2010 · CA
A Phase I Study to Evaluate the Safety and Immunogenicity of HPV 16 L2 11-200$355,234
R01 · FY2009 · CA · contact PI
Ll capsomeres as a next generation preventive HPV vaccine$313,322
P50 · FY2009 · CA
Development of a Pan-Oncogenic HPV Preventive Vaccine$312,734
P50 · FY2009 · CA
A Phase I Study to Evaluate the Safety and Immunogenicity of HPV 16 L2 11-200$411,728
R01 · FY2008 · CA · contact PI